ABSTRACT

Funding for COVID-19 Vaccines: An Overview [Updated January 11, 2021]   [open pdf - 716KB]

From the Document: "The U.S. Food and Drug Administration (FDA) has authorized for emergency use Coronavirus Disease 2019 (COVID-19) vaccines sponsored by Pfizer/BioNTech and Moderna. Several other COVID-19 vaccines are currently in clinical trials; additional vaccines may become available within months. Operation Warp Speed (OWS)--the COVID-19 medical countermeasure initiative led by the Department of Health and Human Services (HHS) and the Department of Defense (DOD)--has contracted with manufacturers to purchase hundreds of millions of doses (including Pfizer/BioNTech and Moderna's vaccines) and related supplies. OWS is also planning and implementing a nationwide vaccine program. OWS has thus far been financed largely by emergency funding provided in the coronavirus supplemental appropriations acts. [...] This Insight provides overviews of supplemental appropriations for selected vaccine-related activities and available information on allocations and obligations. It does not address health care financing issues related to vaccine administration or regular appropriations."

Report Number:
CRS Insight, IN11556
Author:
Publisher:
Date:
2021-01-11
Series:
Copyright:
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations